FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings
Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinom...
Saved in:
Published in | European journal of nuclear medicine and molecular imaging Vol. 30; no. 2; pp. 288 - 295 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin
Springer
01.02.2003
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7+/-3.4 vs 4.8+/-2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2+/-3.2 vs 3.9+/-2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4+/-2.3 vs 5.2+/-3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas. |
---|---|
AbstractList | Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7±3.4 vs 4.8±2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2±3.2 vs 3.9±2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4±2.3 vs 5.2±3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas. Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7+/-3.4 vs 4.8+/-2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2+/-3.2 vs 3.9+/-2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4+/-2.3 vs 5.2+/-3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas. Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7+/-3.4 vs 4.8+/-2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2+/-3.2 vs 3.9+/-2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4+/-2.3 vs 5.2+/-3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas.Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this tumour entity, only a few fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) studies have been published on gastric carcinomas. The aim of this study was to characterise the FDG uptake of gastric carcinomas by relating it to the histopathological properties of the tumours. Within this context, we focussed particularly on the microscopic growth type according to Lauren since our preliminary observations indicated low FDG accumulation in the non-intestinal growth type compared with the intestinal type. Forty patients with locally advanced gastric carcinomas and ten control subjects were studied by FDG PET (300 MBq i.v., emission scan: 40 min p.i., one bed position, measured transmission, filtered back-projection). Detectability of the tumours was qualitatively assessed by two independent observers. For quantitative analysis the regional tumour uptake was measured by standardised uptake values (SUV normalised to the body surface area) using a region of interest technique. Qualitative and quantitative analyses were performed with respect to the microscopic growth type according to Lauren (intestinal type vs non-intestinal type). Other histopathological characteristics were also assessed: mucus content, grading, tumour extension and tumour location. In 36 patients the survival rates were compared for detectable vs non-detectable tumours and for tumour FDG uptake above and below the median. Only 24 of the 40 locally advanced gastric carcinomas (60%) were detected by FDG PET. The detection rate for tumours of the intestinal type was significantly higher than that for tumours of the non-intestinal type (83% vs 41%, P=0.01). Only 2/18 intestinal type tumours contained extracellular or intracellular mucus whereas 17/22 non-intestinal tumours did so (P<0.01). The mean SUV was significantly different between the intestinal type and the non-intestinal type (6.7+/-3.4 vs 4.8+/-2.8, P=0.03), between non-mucus-containing tumours and mucus-containing tumours (7.2+/-3.2 vs 3.9+/-2.1, P<0.01) and between grade 2 tumours and grade 3 tumours (7.4+/-2.3 vs 5.2+/-3.3, P=0.02). The survival rate was not significantly different in patients with detectable tumours on FDG PET and patients with non-detectable tumours (P=0.85). It is concluded that advanced malignant tumours with a poor prognosis may show low FDG uptake due to special histopathological characteristics. The overall low detection rate of gastric carcinomas is attributable to the frequent occurrence of diffusely growing and mucus-containing tumour types. This may limit the value of FDG PET for diagnosis and therapy monitoring in patients with gastric carcinomas. Furthermore, the intensity of tumour FDG uptake is not predictive of survival in gastric carcinomas. |
Author | Stahl, Alexander Siewert, Jörg-Rüdiger Fink, Ulrich Link, Thomas Schwaiger, Markus Ott, Katja Weber, Wolfgang Becker, Karen |
Author_xml | – sequence: 1 givenname: Alexander surname: Stahl fullname: Stahl, Alexander – sequence: 2 givenname: Katja surname: Ott fullname: Ott, Katja – sequence: 3 givenname: Wolfgang surname: Weber fullname: Weber, Wolfgang – sequence: 4 givenname: Karen surname: Becker fullname: Becker, Karen – sequence: 5 givenname: Thomas surname: Link fullname: Link, Thomas – sequence: 6 givenname: Jörg-Rüdiger surname: Siewert fullname: Siewert, Jörg-Rüdiger – sequence: 7 givenname: Markus surname: Schwaiger fullname: Schwaiger, Markus – sequence: 8 givenname: Ulrich surname: Fink fullname: Fink, Ulrich |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14608226$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/12552348$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kcluFDEQhi0URBZ4AC7IQoJbEy_dXrihbESKFA7hbHm8zDjy2IPtAeXt42YGIuUQWa7y4asq1_8fg4OUkwPgPUZfMEL8tCJEJjn0OGBE5DC9AkeYYTlwJOTB_zdHh-C41nuEsCBCvgGHmEwToaM4AuXy_Ar-uLiDYa2XIS1h9jBmo2N8gNr-1sk4C5e6thIMNLqYkPJa16_Q5FJc1C3kBP-EtoIu2VxN3nROJwtXoba80W2VY16G3hD6kGyfUN-C117H6t7t8wn4eXlxd_Z9uLm9uj77djMYOo1tkNxwbeno0CQIs9w7zx12FGlBrGGWLeYrPaHCaskI9cITTwlfMLegZKIn4POu76bkX1tXm1qHalyMOrm8rYoTKQSVrIMfn4H3eVtS_5sieGT9CNyhD3tou1g7qzalK1Ye1D8pO_BpD-ja1_WlaxfqEzcyJAiZp-EdZ0qutTj_hCA126p2tqoe1Wyrmlfhz2pMaH-1b0WH-ELlIxBVpq8 |
CitedBy_id | crossref_primary_10_1097_MCP_0000000000000297 crossref_primary_10_1016_j_ejrad_2017_06_022 crossref_primary_10_1016_j_semradonc_2012_09_001 crossref_primary_10_1007_BF02984984 crossref_primary_10_1158_1078_0432_CCR_04_0599 crossref_primary_10_2342_ymj_57_171 crossref_primary_10_1007_s00423_011_0805_8 crossref_primary_10_1089_cbr_2017_2186 crossref_primary_10_1097_MNM_0000000000001481 crossref_primary_10_1002_jso_21356 crossref_primary_10_1016_S0123_9015_11_70078_6 crossref_primary_10_1016_j_rcl_2004_08_003 crossref_primary_10_1007_s10147_013_0598_6 crossref_primary_10_1055_s_0041_1735217 crossref_primary_10_1111_j_1759_7714_2011_00060_x crossref_primary_10_1097_MD_0000000000016690 crossref_primary_10_4251_wjgo_v14_i8_1406 crossref_primary_10_1021_acsmedchemlett_6b00498 crossref_primary_10_1002_jso_24190 crossref_primary_10_7704_kjhugr_2013_13_3_158 crossref_primary_10_1016_j_mpmed_2015_01_007 crossref_primary_10_1007_BF03034001 crossref_primary_10_1097_MNM_0000000000001489 crossref_primary_10_1007_s00259_019_04429_x crossref_primary_10_1007_s00432_010_0852_5 crossref_primary_10_1186_s12957_015_0743_y crossref_primary_10_1007_s00259_008_0970_3 crossref_primary_10_5230_jgc_2014_14_1_1 crossref_primary_10_1007_s10120_006_0374_7 crossref_primary_10_1053_j_semnuclmed_2004_03_005 crossref_primary_10_1097_RLU_0000000000005748 crossref_primary_10_1245_s10434_024_15103_4 crossref_primary_10_12812_ksms_2015_17_1_111 crossref_primary_10_1007_s00259_020_04977_7 crossref_primary_10_47102_annals_acadmedsg_V33N2p186 crossref_primary_10_1007_s00261_020_02503_9 crossref_primary_10_1177_0300060519892417 crossref_primary_10_5230_jgc_2012_12_3_179 crossref_primary_10_4166_kjg_2014_63_6_348 crossref_primary_10_1259_bjr_29946900 crossref_primary_10_4166_kjg_2012_59_5_347 crossref_primary_10_4166_kjg_2013_61_6_303 crossref_primary_10_3892_mco_2018_1767 crossref_primary_10_7704_kjhugr_2013_13_3_133 crossref_primary_10_1097_RLU_0000000000004764 crossref_primary_10_1097_01_mnm_0000134329_30912_49 crossref_primary_10_4166_kjg_2014_63_2_66 crossref_primary_10_1016_j_ejso_2008_11_010 crossref_primary_10_1007_s10120_008_0492_5 crossref_primary_10_2967_jnmt_116_181479 crossref_primary_10_1002_cncr_27550 crossref_primary_10_1007_s00261_008_9420_8 crossref_primary_10_1007_s10120_007_0448_1 crossref_primary_10_1155_2013_696423 crossref_primary_10_1016_j_cpet_2008_09_002 crossref_primary_10_12677_ACM_2023_13102132 crossref_primary_10_1097_RLU_0b013e31823ea44d crossref_primary_10_1186_s12885_017_3271_z crossref_primary_10_1007_s00259_007_0477_3 crossref_primary_10_6004_jnccn_2022_0008 crossref_primary_10_1007_s00104_011_2127_3 crossref_primary_10_1007_s00261_016_0647_5 crossref_primary_10_1007_s10120_011_0069_6 crossref_primary_10_1186_s43055_019_0067_y crossref_primary_10_1200_JCO_2014_59_9787 crossref_primary_10_5230_jgc_2018_18_e23 crossref_primary_10_1067_j_cpsurg_2006_06_003 crossref_primary_10_1200_JCO_2006_06_7801 crossref_primary_10_1016_j_bpg_2005_08_001 crossref_primary_10_1111_j_1442_2050_2006_00617_x crossref_primary_10_1007_s40336_024_00633_4 crossref_primary_10_1183_16000617_0065_2018 crossref_primary_10_1007_s00330_019_06370_x crossref_primary_10_1097_RLU_0b013e3181b81d80 crossref_primary_10_1007_s13139_019_00622_w crossref_primary_10_1007_s00104_006_1270_8 crossref_primary_10_1007_s00104_009_1731_y crossref_primary_10_1016_j_gtc_2018_04_011 crossref_primary_10_1007_s00268_003_7191_5 crossref_primary_10_1155_2018_1794524 crossref_primary_10_1016_j_rcl_2021_06_001 crossref_primary_10_1016_S0399_8320_06_73306_1 crossref_primary_10_4166_kjg_2014_64_6_340 crossref_primary_10_1097_MD_0000000000000864 crossref_primary_10_1053_j_semnuclmed_2005_12_002 crossref_primary_10_1007_s00261_005_0031_3 crossref_primary_10_3109_07357907_2014_911877 crossref_primary_10_1016_j_lpm_2007_03_048 crossref_primary_10_3390_cancers3022141 crossref_primary_10_1097_MNM_0b013e3283299a2f crossref_primary_10_1159_000350878 crossref_primary_10_1016_j_radonc_2010_07_019 crossref_primary_10_2967_jnumed_120_258467 crossref_primary_10_3413_Nukmed_0504_12_05 crossref_primary_10_1007_s12149_013_0791_8 crossref_primary_10_1097_01_cco_0000128276_13585_fa crossref_primary_10_1245_s10434_011_1743_y crossref_primary_10_1007_s13139_015_0327_3 crossref_primary_10_4274_nts_galenos_2024_0011 crossref_primary_10_1111_ajco_12833 crossref_primary_10_1007_s10120_018_0847_5 crossref_primary_10_1016_j_rcl_2020_11_002 crossref_primary_10_1016_j_ejro_2020_01_001 crossref_primary_10_1007_s10120_021_01223_3 crossref_primary_10_3892_mco_2019_1815 crossref_primary_10_4103_ijnm_ijnm_69_24 crossref_primary_10_1007_s11604_014_0294_0 crossref_primary_10_1186_s43055_021_00656_1 crossref_primary_10_2967_jnumed_107_050187 crossref_primary_10_1007_s00423_010_0738_7 crossref_primary_10_1007_s10120_012_0165_2 crossref_primary_10_1038_sj_bjc_6604062 crossref_primary_10_1158_1078_0432_CCR_07_0934 crossref_primary_10_1157_13079285 crossref_primary_10_1001_jamasurg_2021_5340 crossref_primary_10_1002_cncr_21074 crossref_primary_10_1016_j_clinimag_2011_12_014 crossref_primary_10_1016_j_suc_2020_02_004 crossref_primary_10_1245_s10434_014_3848_6 crossref_primary_10_1097_MNM_0000000000001761 crossref_primary_10_3348_kjr_2006_7_4_249 crossref_primary_10_1159_000381287 crossref_primary_10_1016_j_ejrad_2010_02_005 crossref_primary_10_1097_RLU_0000000000000667 crossref_primary_10_1016_j_cpet_2015_03_008 crossref_primary_10_1200_JCO_2003_06_574 crossref_primary_10_1007_s00259_010_1611_1 crossref_primary_10_1016_S1879_8527_12_55045_8 crossref_primary_10_5230_jgc_2023_23_e11 crossref_primary_10_1002_jcla_22364 crossref_primary_10_1016_j_critrevonc_2005_09_004 crossref_primary_10_1245_s10434_009_0387_7 crossref_primary_10_1016_j_cpet_2025_01_004 crossref_primary_10_1007_s13139_010_0058_4 crossref_primary_10_3748_wjg_v21_i37_10502 crossref_primary_10_1007_s00761_005_0881_x crossref_primary_10_1007_s12149_016_1059_x crossref_primary_10_1007_s00761_008_1333_1 crossref_primary_10_1016_j_ejrad_2013_01_021 crossref_primary_10_1007_s00261_016_0788_6 crossref_primary_10_1016_j_ejro_2020_100268 crossref_primary_10_5230_jgc_2014_14_2_87 crossref_primary_10_1200_JCO_2011_39_7422 crossref_primary_10_2169_internalmedicine_0013_17 crossref_primary_10_1159_000436972 crossref_primary_10_1007_s11377_010_0432_x crossref_primary_10_1371_journal_pone_0166836 crossref_primary_10_1093_annonc_mdq289 crossref_primary_10_1007_s00595_020_02018_2 crossref_primary_10_1007_s12149_007_0061_8 crossref_primary_10_1007_s12149_009_0291_z crossref_primary_10_1016_j_ejrad_2013_01_014 crossref_primary_10_2217_iim_12_5 crossref_primary_10_4103_ijnm_ijnm_208_21 crossref_primary_10_1007_s00259_022_05799_5 crossref_primary_10_1016_j_dld_2015_02_005 crossref_primary_10_1007_s00104_007_1381_x crossref_primary_10_1016_j_soc_2011_09_005 crossref_primary_10_1080_00365520903121701 crossref_primary_10_1097_01_rlu_0000255241_97811_4d crossref_primary_10_24938_kutfd_1014164 crossref_primary_10_1007_s00259_015_3249_5 crossref_primary_10_1148_rg_245035725 crossref_primary_10_18632_oncotarget_11574 crossref_primary_10_2967_jnumed_115_160580 crossref_primary_10_9738_INTSURG_D_16_00006_1 crossref_primary_10_1016_j_rcl_2013_05_003 crossref_primary_10_1186_s40001_023_00997_9 crossref_primary_10_1007_s10120_024_01484_8 crossref_primary_10_1007_s00330_009_1405_7 crossref_primary_10_1371_journal_pone_0050914 crossref_primary_10_3390_cancers14112668 crossref_primary_10_1007_s00259_012_2164_2 crossref_primary_10_3390_curroncol29090513 crossref_primary_10_3390_ijms21114012 crossref_primary_10_2967_jnumed_114_150946 crossref_primary_10_1155_2019_9564627 crossref_primary_10_2967_jnumed_115_163295 crossref_primary_10_1007_s00261_019_02065_5 crossref_primary_10_1186_1471_2407_9_73 crossref_primary_10_3389_fonc_2024_1427649 crossref_primary_10_1097_MNM_0b013e32833823ac crossref_primary_10_1002_jso_23180 crossref_primary_10_1007_s00259_022_06021_2 crossref_primary_10_1016_j_suc_2012_07_011 crossref_primary_10_1016_j_ijscr_2017_05_026 crossref_primary_10_1097_01_mnm_0000135042_54461_f6 crossref_primary_10_3390_cancers13030420 crossref_primary_10_1007_s00259_022_06095_y crossref_primary_10_1007_s13139_013_0243_3 crossref_primary_10_1053_j_semnuclmed_2015_03_002 crossref_primary_10_1177_15330338241277389 crossref_primary_10_1007_s00259_012_2116_x crossref_primary_10_1007_s10120_017_0739_0 crossref_primary_10_2967_jnumed_112_110239 crossref_primary_10_1177_17588359211065153 crossref_primary_10_1097_01_rlu_0000191575_85516_ef crossref_primary_10_2967_jnumed_116_182675 crossref_primary_10_1007_s00259_021_05441_w crossref_primary_10_5230_jgc_2025_25_e11 crossref_primary_10_1007_BF02984649 crossref_primary_10_3389_fsurg_2018_00041 crossref_primary_10_1007_s11605_014_2701_3 crossref_primary_10_3748_wjg_v21_i19_5901 crossref_primary_10_1007_s10120_011_0017_5 crossref_primary_10_1148_rg_261055078 crossref_primary_10_1016_j_suronc_2018_11_002 crossref_primary_10_1007_s00330_022_08743_1 crossref_primary_10_1097_RLU_0000000000002028 crossref_primary_10_2169_internalmedicine_48_1858 crossref_primary_10_3390_cancers6041821 crossref_primary_10_1007_BF02984657 crossref_primary_10_1007_s00259_005_1887_8 crossref_primary_10_1007_s13139_012_0149_5 crossref_primary_10_1148_radiol_2020203275 crossref_primary_10_1002_jso_21224 crossref_primary_10_1016_j_giec_2008_05_006 |
ContentType | Journal Article |
Copyright | 2003 INIST-CNRS Springer-Verlag 2003 |
Copyright_xml | – notice: 2003 INIST-CNRS – notice: Springer-Verlag 2003 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ P5Z P62 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
DOI | 10.1007/s00259-002-1029-5 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection Proquest Medical Database Biological Science Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Collection ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Advanced Technologies & Aerospace Database Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | ProQuest Central Student MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1619-7089 |
EndPage | 295 |
ExternalDocumentID | 819051731 12552348 14608226 10_1007_s00259_002_1029_5 |
Genre | Validation Studies Evaluation Studies Journal Article Case Reports Report Case Study |
GroupedDBID | --- -Y2 -~C .86 .GJ 04C 06C 06D 0R~ 0VY 1N0 29G 29~ 2JN 2JY 2LR 2P1 2VQ 2~H 36B 4.4 406 40D 53G 5GY 5QI 5RE 5VS 6NX 78A 7RV 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8UJ 95- 95. 95~ AACDK AAHNG AAIAL AAJBT AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYQN AAYTO AAYXX AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDBF ABECU ABFSG ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABLJU ABMNI ABMQK ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACIWK ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSTC ACUDM ACUHS ACZOJ ADBBV ADHIR ADHKG ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AEVLU AEXYK AEZWR AFBBN AFDZB AFEXP AFFNX AFHIU AFJLC AFKRA AFLOW AFOHR AFQWF AFRAH AFWTZ AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGVAE AGWIL AHAVH AHBYD AHIZS AHKAY AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AOCGG ARAPS ATHPR AXYYD AYFIA AZFZN B-. B0M BA0 BBNVY BDATZ BENPR BGLVJ BGNMA BHPHI BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU CITATION COF CSCUP DDRTE DNIVK DPUIP DU5 EAD EAP EAS EBB EBC EBD EBLON EBO EBS EBX EHN EIHBH EIOEI EJD EMB EMK EMOBN EN4 EPL EPT ESX EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FSGXE FYUFA G-Y G-Z GGCAI GNWQR GQ7 GRRUI H13 HCIFZ HF~ HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ IHE IJ- IKXTQ IMOTQ IWAJR IZIGR IZQ I~X I~Z J-C JBSCW JCJTX JZLTJ KDC KPH LAS LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O9G OAM OVD P19 P62 P9S PF0 PHGZM PHGZT PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK Q~Q R89 R9I RNI RNS ROL RPX RSV RZK S1Z S26 S27 S28 S37 SAP SCLPG SDH SISQX SJYHP SMD SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 T13 T16 TEORI TH9 TSG TSK TT1 TUS UG4 UKHRP UOJIU UTJUX UZXMN VFIZW W23 W48 WK8 WOW YLTOR Z8Z ZMTXR ~8M ABRTQ IQODW PJZUB PPXIY PQGLB -5E -5G -BR .VR 199 203 2KM 30V 3V. 67Z 96X AAAVM ABNWP ABPLI ADINQ ALWAN ARMRJ CGR CUY CVF DL5 ECM EIF ESBYG FRRFC FWDCC GGRSB GQ6 GQ8 GXS HG5 I09 ITM IXC J0Z NPM O93 O9I O9J QOR QOS RRX S3B SNE SZN U2A U9L VC2 Z45 Z7R Z7U Z7W Z7X Z7Y Z7Z Z81 Z82 Z83 Z87 Z88 Z8M Z8O Z8Q Z8R Z8S Z8T Z8U Z8V Z8W Z91 7TK 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS PUEGO 7X8 |
ID | FETCH-LOGICAL-c354t-97c7ad34e05826d7fef7e1e30a82dc6d6b6d6b9f238da9623f8f2f327b6eb3253 |
IEDL.DBID | 7X7 |
ISSN | 1619-7070 |
IngestDate | Fri Jul 11 12:03:24 EDT 2025 Sat Aug 23 13:39:35 EDT 2025 Wed Feb 19 01:36:25 EST 2025 Mon Jul 21 09:17:31 EDT 2025 Tue Jul 01 02:19:39 EDT 2025 Thu Apr 24 23:05:46 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Radionuclide study Human Stomach Focal lesion Carcinoma Malignant tumor Pathology Cohort study Digestive diseases Advanced stage Diagnosis Endoscopy Pharmacokinetics Radiopharmaceuticals Comparative study Gastric disease Positron Emission tomography |
Language | English |
License | http://www.springer.com/tdm CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c354t-97c7ad34e05826d7fef7e1e30a82dc6d6b6d6b9f238da9623f8f2f327b6eb3253 |
Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Report-1 content type line 23 ObjectType-Feature-5 ObjectType-Undefined-3 ObjectType-Article-4 |
PMID | 12552348 |
PQID | 214646481 |
PQPubID | 42802 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_72988396 proquest_journals_214646481 pubmed_primary_12552348 pascalfrancis_primary_14608226 crossref_primary_10_1007_s00259_002_1029_5 crossref_citationtrail_10_1007_s00259_002_1029_5 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2003-02-01 |
PublicationDateYYYYMMDD | 2003-02-01 |
PublicationDate_xml | – month: 02 year: 2003 text: 2003-02-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin – name: Germany – name: Heidelberg |
PublicationTitle | European journal of nuclear medicine and molecular imaging |
PublicationTitleAlternate | Eur J Nucl Med Mol Imaging |
PublicationYear | 2003 |
Publisher | Springer Springer Nature B.V |
Publisher_xml | – name: Springer – name: Springer Nature B.V |
SSID | ssj0018289 |
Score | 2.2203498 |
Snippet | Gastric cancer carries a poor prognosis and is the second most frequent cause of cancer-related death worldwide. In spite of the clinical importance of this... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 288 |
SubjectTerms | Biological and medical sciences Digestion. Liver. Biliary tract. Spleen. Pancreas Fluorodeoxyglucose F18 Follow-Up Studies Gastroenterology. Liver. Pancreas. Abdomen Gastroscopy - methods Humans Investigative techniques, diagnostic techniques (general aspects) Male Medical sciences Middle Aged Observer Variation Prognosis Radionuclide Imaging Radionuclide investigations Radiopharmaceuticals Reference Values Reproducibility of Results Retrospective Studies Sensitivity and Specificity Single-Blind Method Statistics as Topic Stomach Neoplasms - diagnosis Stomach Neoplasms - diagnostic imaging Stomach Neoplasms - mortality Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Survival Analysis Survival Rate Tumors |
Title | FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings |
URI | https://www.ncbi.nlm.nih.gov/pubmed/12552348 https://www.proquest.com/docview/214646481 https://www.proquest.com/docview/72988396 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB61IKFKqCotjy1l60NPlSKysRM7XBALG1AlEKpA2luU-LFCgmQhy6H_vjPOA3EARXEOsX3w2OP5POP5AH4JlQqXIlJ1JWITVHgyKKWyAY_tRDghrA7pcvLlVXJxK_7M43kXm9N0YZW9TvSK2tSazsgPiYAaHzU5Xj4GRBpFztWOQeMjrFPmMorokvMBb00ITBDeQowQSJzavVMz9DlE0e4PPLMHBYDEr7alzWXR4Ai5ltribdvT70HZF_jcGY_spJX2Fnyw1VfYuOzc49_gKTs7Z9ezG3b34MmHWO2Y36zu_7He2c8WBVF1aKaJRaii8KAjpomjo42KY3Qyy2xlarqwgvWKyjCflZjIi3tVybyvu1o023CbzW5OL4KOVCHQPBarIJVaFoYLG8aILIx01kk7sTwsVGR0YpKS3tThVm6KFI0jp1zkeCTLBHF3FPMdWKvqyu4BQwVVpihOxDyoB8pQWWHRvogSbowzho8g7Mc0113GcSK-uM-HXMleDDmWOYkhj0fwe2iybNNtvFd5_EpQLy1EQonskxHs95LLu6XZ5MNEGsHP4S-uKXKUFJWtn5scAYdCwxHb77bifukZEVjEhfr-bs_78MnH_Png7h-wtnp6tgdou6zKsZ-hWKrsfAzrJ9OzaYbf6ezq-u9_RVnvJw |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB4hkGilChX6WqDgQ3upFDUbO4mDVKGqsCyFRT0sEjc38QNVgmQhixA_iv_YGeeBOMANRckltg-e8Xg-z3g-gC9CZsJliFRdgdgEDV4aFKm0AY_tUDghrA7pcvLkJBmfit9n8dkC3Hd3YSitsrOJ3lCbStMZ-XcioMZHDndnVwGRRlFwtWPQaLTiyN7dImKrfxzuoXi_RtFof_prHLSkAoHmsZgHWarT3HBhwxg9a5M661I7tDzMZWR0YpKC3szhVmbyDJ0DJ13keJQWCeLOiEgi0OIvCc4zWlBydNAHLQi8EL5DTBKkuJS6IGroa5Yizgg8kwglnMSPtsE3s7xGibiGSuNpX9fveaO3sNI6q-xno12rsGDLNVietOH4d3A92jtgf_an7N-lJztilWN-c7y4Y11yATvPiRpEM02sRSWlI-0wTZwgTRYeo5NgZktT0QUZbJeXhvkqyESW3Jlm5mPr5Xn9Hk5fZL4_wGJZlfYTMDSIRYbqgxgL7U4RSiss-jNRwo1xxvABhN2cKt1WOCeijQvV12b2YlD4VSQGFQ_gW99l1pT3eK7x1iNBPfQQCRXOTwaw0UlOtaagVr3iDmC7_4trmAIzeWmrm1ohwJHoqGL_j424H0ZGxBdxIdefHXkbXo2nk2N1fHhytAGvfb6hTyzfhMX59Y39jH7TvNjy2srg70svj_8YXSjc |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LS91AFD6IBSkUaWsft1qdRd0IwSQzySQFKcXrrdYHLhTubprMQwqa3JorxZ_mv_OcyUNc6E5CssnMLHIec76cM-cD-CayXLgckaorEZugw5NBKTMb8MRGwglhdUiHk49P0v1z8XuaTBfgrj8LQ2WVvU_0jtrUmv6RbxMBNV5ZtO26qojT8eTH7F9ABFKUaO3ZNFoNObS3_xG9NTsHYxT1ZhxP9s5294OOYCDQPBHzIJdaFoYLGyYYZRvprJM2sjwsstjo1KQl3bnDbc0UOQYKLnOx47EsU8SgMRFGoPd_JXkSkYnJ6YD1IgIyhPUQnwQSzapPqIa-fylijsCzilDxSfJoS3wzKxqUjmtpNZ6Oe_3-N3kLy13gyn62mvYOFmz1HpaOu9T8ClxPxr_Y6d4Z-3vliY9Y7ZjfKC9vWV9owC4KognRTBODUUWlSd-ZJn6QtiKP0V9hZitT02EZHFdUhvmOyESc3Ltp5vPs1UXzAc5f5Ht_hMWqruxnYOgcyxxVCfEW-qAyzKywGNvEKTfGGcNHEPbfVOmu2zmRblyqoU-zF4PCpyIxqGQEW8OUWdvq47nB648E9TBDpNREPx3Bai851bmFRg1KPIKN4S3aMyVpisrWN41CsJNh0IrzP7XiflgZ0V_MRfbl2ZU3YAkNQx0dnByuwmtfeuhrzNdgcX59Y79iCDUv172yMvjz0tZxD73hLQk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FDG+PET+imaging+of+locally+advanced+gastric+carcinomas%3A+correlation+with+endoscopic+and+histopathological+findings&rft.jtitle=European+journal+of+nuclear+medicine+and+molecular+imaging&rft.au=Stahl%2C+Alexander&rft.au=Ott%2C+Katja&rft.au=Weber%2C+Wolfgang&rft.au=Becker%2C+Karen&rft.date=2003-02-01&rft.issn=1619-7070&rft.eissn=1619-7089&rft.volume=30&rft.issue=2&rft.spage=288&rft.epage=295&rft_id=info:doi/10.1007%2Fs00259-002-1029-5&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s00259_002_1029_5 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1619-7070&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1619-7070&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1619-7070&client=summon |